AMRI AMRI
today announced that its Albuquerque, N.M. sterile injectable facility has
resumed full manufacturing operations. As previously announced, in September
2014 AMRI identified an environmental deviation in one manufacturing suite as
a result of a weather related business interruption. The resulting remediation
has now been completed.
Commenting on its operations, William S. Marth, AMRI's President and Chief
Executive Officer, said: "We are pleased to report that all suites at our
OsoBio Albuquerque aseptic manufacturing facility are fully operational. I
would like to acknowledge and thank our colleagues and vendors for their
dedicated efforts in remediating the affected manufacturing suite as quickly
as possible."
AMRI's OsoBio facility is an established provider of cGMP manufacturing and
sterile filling of parenteral drugs using specialized technologies, including
lyophilization. With its cGMP aseptic filling expertise, OsoBio supports
commercial scale production of liquid-filled and lyophilized parenterals.
These services are provided for both small molecule drug products as well as
biologicals. Oso Biopharmaceutical Manufacturing was acquired by AMRI in July
2014.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in